Renovaro Biosciences (NASDAQ: RENB) has announced the publication of a peer-reviewed study in the journal Vaccines, showcasing preclinical data on its genetically engineered dendritic cell therapy platform. The study demonstrates the platform's ability to significantly reduce pancreatic tumor burden and activate robust immune responses in humanized mouse models. Key findings include a reduction in tumor weight and volume by up to 81.7%, increased immune cell activity, and selective cytotoxicity against pancreatic tumor cells. The platform's scalable, off-the-shelf approach uses CD34⁺ hematopoietic stem cells, enhancing its clinical utility. Renovaro plans to initiate further preclinical studies across multiple tumor types and explore combination strategies with other therapies. The full study is available in Vaccines.